The estimated Net Worth of Peter Kolchinsky is at least $111 Milione dollars as of 23 June 2020. Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $53,168,741 and over the last 10 years he sold WVE stock worth over $58,095,632. In addition, he makes $151,598 as Independent Director at Wave Life Sciences.
Sign up
Peter Kolchinsky WVE stock SEC Form 4 insiders trading
Peter has made over 5 trades of the Wave Life Sciences stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,000,000 units of WVE stock worth $80,000,000 on 23 June 2020.
The largest trade he's ever made was buying 4,545,455 units of Wave Life Sciences stock on 11 December 2018 worth over $50,000,005. On average, Peter trades about 366,737 units every 19 days since 2014. As of 23 June 2020 he still owns at least 9,011,651 units of Wave Life Sciences stock.
You can see the complete history of Peter Kolchinsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Kolchinsky biography
Dr. Peter Kolchinsky Ph.D. serves as Independent Director of the Company. Dr. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. RA Capital Management, L.P. is the investment manager of RA Capital Healthcare Fund, L.P. He serves as a member of the board of directors of a number of private companies. Dr. Kolchinsky also leads RA Capital’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur’s Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor’s degree in Biology from Cornell University.
What is the salary of Peter Kolchinsky?
As the Independent Director of Wave Life Sciences, the total compensation of Peter Kolchinsky at Wave Life Sciences is $151,598. There are 12 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
How old is Peter Kolchinsky?
Peter Kolchinsky is 43, he's been the Independent Director of Wave Life Sciences since 2015. There are 15 older and 2 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
What's Peter Kolchinsky's mailing address?
Peter's mailing address filed with the SEC is C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116.
Insiders trading at Wave Life Sciences
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... e Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
What does Wave Life Sciences do?
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
What does Wave Life Sciences's logo look like?
Complete history of Peter Kolchinsky stock trades at Dicerna Pharmaceuticals Inc, Wave Life Sciences e Forma Therapeutics
Wave Life Sciences executives and stock owners
Wave Life Sciences executives and other stock owners filed with the SEC include:
-
Paul Bolno,
President, Chief Executive Officer, Director -
Christopher Francis,
Senior Vice President - Corporate Development, Head of Emerging Areas -
Michael Panzara,
Chief Medical Officer -
Chandra Vargeese,
Senior Vice President, Head of Drug Discovery -
Dr. Paul B. Bolno M.B.A., M.D., MBA,
Pres, CEO & Director -
Dr. Michael A. Panzara M.D., M.P.H., MPH,
Chief Medical Officer and Head of Therapeutics Discovery & Devel. -
Dr. Chandra Vargeese Ph.D.,
Chief Technology Officer -
Gregory Verdine,
Director -
Mark Corrigan,
Independent Director -
Amy Pott,
Independent Director -
Heidi Wagner,
Independent Director -
Christian Henry,
Independent Chairman of the Board -
Peter Kolchinsky,
Independent Director -
Ken Takanashi,
Independent Director -
Adrian Rawcliffe,
Independent Director -
Koji Miura,
Independent Director -
Kenneth Rhodes,
Senior Vice President - Therapeutics Discovery -
David Gaiero,
Interim Chief Financial Officer -
Kate Rausch,
Investor Relations -
Anne-Marie Li-Kwai-Cheung,
Sr. VP of Regulatory Affairs, Compliance & Policy -
Dr. Sridhar Vaddeboina Ph.D.,
Sr. VP of Chemistry, Manufacturing & Controls -
Jose Juves,
Sr. VP of Corp. Affairs & Patient Advocacy -
Jonathan Rosin,
Chief HR Officer -
Dr. Christopher Francis Ph.D.,
Sr. VP of Corp. Devel. & Head of Emerging Areas -
Linda Rockett J.D.,
Gen. Counsel -
Kyle B. Moran CFA,
CFO & Principal Accounting Officer -
Chris Francis,
See Remarks -
Plc Gsk,
10% owner -
Keith Regnante,
Chief Financial Officer -
Takeshi Wada,
Director -
Ken Shin Nippon Biomedical ...,
-
Masaharu Kagoshima Shinsang...,
-
Roberto Guerciolini,
See Remarks -
Masaharu Tanaka,
Director -
Peter Kolchinsky,
Director -
Capital Management, Llc Kol...,
-
Mark Baldry,
Chief Commerical Officer -
Capital Management, L.P.Ra ...,
-
Kyle Moran,
Chief Financial Officer -
Aik Na Tan,